

CLAIMS

1. A therapeutic agent for myocardial pathology used for noninvasive administration comprising a hepatocyte growth factor (HGF) gene as the effective ingredient.
2. The therapeutic agent of claim 1, which is used for administration of the HGF gene into the cardiac muscle.
3. The therapeutic agent of claim 1 or 2, wherein the HGF gene is in the form of Sendai virus (HVJ)-liposome.
4. The therapeutic agent of claim 2 or 3, which is used for noninvasive administration to the affected part of the cardiac muscle under the usage of echo.
5. The therapeutic agent of any of claims 1 to 4, which is to be administered at least 8 times, once a week.
6. The therapeutic agent of any of claims 1 to 5, wherein at least 10 μ g of the HGF gene is used.
7. The therapeutic agent of any of claims 1 to 6, wherein the myocardial pathology is selected from the group consisting of cardiomyopathy, angina pectoris and heart failure.
8. A gene therapy agent used for noninvasive administration of a gene into an affected part of a tissue under the usage of echo, which comprises genes effective for the treatment of a disorder as the effective ingredient.
9. The gene therapy agent of claim 8, wherein the affected part of the tissue is the cardiac muscle.
10. The gene therapy agent of claim 8 or 9, wherein the gene is an HGF gene.
11. A method for gene therapy for myocardial pathology, which comprises the noninvasive administration of an HGF gene into the cardiac muscle of a mammal, including a human.
12. The method for gene therapy of claim 11, wherein the HGF gene is in the form of Sendai virus (HVJ)-liposome.
13. The method for gene therapy of claim 11 or 12, wherein the HGF gene is administered noninvasively to a part of an affected cardiac muscle under the usage of echo.
14. The method for gene therapy of any of claims 11 to 13, wherein

the HGF gene is administered at least 8 times, once per week.

15. The method for gene therapy of any of claims 11 to 14, wherein the myocardial pathology is selected from the group consisting of cardiomyopathy, angina pectoris and heart failure.

5 16. A method for gene therapy, which comprises the noninvasive administration of genes effective for the treatment of a disorder into an affected part of a tissue under the usage of echo.

17. The method for gene therapy of claim 16, wherein the affected tissue is the cardiac muscle.

10 18. The method for gene therapy of claim 16 or 17, wherein the gene is an HGF gene.

19. Use of an HGF gene for the production of a therapeutic agent for myocardial pathology used for noninvasive administration.

15 20. The use of claim 19, wherein the HGF gene is in the form of Sendai virus (HVJ)-liposome.

21. The use of claim 19 or 20, wherein the therapeutic agent is a therapeutic agent used for the noninvasive administration of the HGF gene to an affected part of the cardiac muscle under the usage of echo.

20 22. The use of any of claims 19 to 21, wherein the myocardial pathology is selected from the group consisting of cardiomyopathy, angina pectoris and heart failure.

23. Use of a gene for the production of a gene therapy agent used for the noninvasive administration of genes effective for the treatment
25 of a disorder into an affected part of a tissue under the usage of echo.

24. The use of claim 23, wherein the affected tissue is cardiac muscle.

25. The use of claim 23 or 24, wherein the gene is an HGF gene.